FDA
-
-
-
-
-
-
-
Sarepta plans regulatory submissions for two Duchenne drugs by April 2026
-
-
-
-
-
-
-
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
-
-
-
-
-
-
-
Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty
-
-
-
-
-
-
-
FDA approves updated ELEVIDYS label with liver injury warning
-
-
-
-
-
-
-
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) PT Raised to $17 at TD Cowen
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) call put ratio 1.7 calls to 1 put into FDA headlines
-
322,964 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

